We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

89 hedge funds and large institutions have $639M invested in Applied Therapeutics in 2024 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 34 increasing their positions, 17 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,571% more call options, than puts

Call options by funds: $45.8M | Put options by funds: $1.71M

210% more capital invested

Capital invested by funds: $206M → $639M (+$433M)

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

100% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 17

25% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 24

9.1% more ownership

Funds ownership: 79.64%88.74% (+9.1%)

7% more funds holding

Funds holding: 8389 (+6)

Holders
89
Holders Change
+6
Holders Change %
+7.23%
% of All Funds
1.28%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
30
Increased
34
Reduced
17
Closed
24
Calls
$45.8M
Puts
$1.71M
Net Calls
+$44.1M
Net Calls Change
+$18.1M
Name Holding Trade Value Shares
Change
Change in
Stake
Northern Trust
51
Northern Trust
Illinois
$724K -$646 -144 -0.1%
HF
52
HRT Financial
New York
$672K +$444K +98,879 New
EI
53
EAM Investors
California
$632K -$404K -89,998 -49%
OAC
54
OMERS Administration Corp
Ontario, Canada
$440K +$232K +51,600 +394%
RB
55
Richmond Brothers
Michigan
$420K -$278K -61,827 -50%
Barclays
56
Barclays
United Kingdom
$417K +$275K +61,272 New
ECM
57
ExodusPoint Capital Management
New York
$413K +$273K +60,795 New
MTIM
58
Marathon Trading Investment Management
Pennsylvania
$401K +$265K +59,000 New
BHCM
59
Brevan Howard Capital Management
Jersey
$322K +$213K +47,356 New
JF
60
Jump Financial
Illinois
$296K +$87.1K +19,398 +80%
EC
61
EntryPoint Capital
New York
$272K +$180K +40,070 New
RZH
62
Relyea Zuckerberg Hanson
Connecticut
$272K
EGM
63
Engineers Gate Manager
New York
$269K +$178K +39,631 New
PAS
64
Point72 Asia (Singapore)
Singapore
$253K +$154K +34,245 +1,181%
Bank of America
65
Bank of America
North Carolina
$242K -$40.8K -9,086 -20%
DA
66
Denali Advisors
California
$228K +$151K +33,600 New
CM
67
Caption Management
Oklahoma
$213K +$141K +31,300 New
LP
68
LMR Partners
United Kingdom
$190K +$126K +28,013 New
YIH
69
Y-Intercept (HK)
Hong Kong
$184K +$71.7K +15,969 +145%
PCMH
70
Polymer Capital Management (HK)
Hong Kong
$176K +$116K +25,826 New
Charles Schwab
71
Charles Schwab
California
$167K
JFG
72
Jefferies Financial Group
New York
$151K +$99.7K +22,200 New
GCP
73
GSA Capital Partners
United Kingdom
$146K +$96.2K +21,431 New
WA
74
WealthTrust Axiom
Pennsylvania
$143K -$98.8K -22,000 -51%
SPS
75
Susquehanna Portfolio Strategies
Pennsylvania
$95.9K -$49.4K -10,996 -44%

APLT Hedge Fund Activity: Q1 2024 in Review

89 of the 6,944 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q1 2024, worth a combined $639M — up 210% from $206M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new APLT positions and 24 closed out — a net gain of 6 holders — while 34 added to existing stakes and 17 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $19.2M. The largest seller was Fidelity Investments, exiting entirely with an estimated $8.13M sold.

  • 89 institutional investors held Applied Therapeutics (APLT) as of Q1 2024, up from 83 in Q4 2023.
  • Funds reported $639M of Applied Therapeutics stock for Q1 2024, up 210% quarter-over-quarter.
  • 30 funds opened new Applied Therapeutics positions in Q1 2024 and 24 closed out, a net change of +6 holders.
  • The largest Applied Therapeutics buyer in Q1 2024 was Janus Henderson Group, an estimated $19.2M added.
  • The largest Applied Therapeutics seller in Q1 2024 was Fidelity Investments, an estimated $8.13M sold.

Based on aggregated 13F filings for Q1 2024.